Objective response to treatment as a potential surrogate marker of survival in breast cancer

Paolo Bruzzi

Research output: Contribution to journalArticlepeer-review

Abstract

Until recently, objective tumor response to chemotherapy was used as the primary endpoint in phase II trials aimed at assessing the anti-tumor activity of new drugs. However, it was not accepted as a surrogate endpoint of survival for efficacy trials in solid tumors, and it was not believed to be associated with survival benefit. The recent demonstration that objective response is indeed a valid surrogate endpoint of survival in colorectal cancer, together with strong indirect evidence supporting a similar role of response in breast cancer, opens new possibilities for both the design of trials in metastatic breast cancer and the clinical decision in individual patients with the disease.

Original languageEnglish
Pages (from-to)144-147
Number of pages4
JournalAnnals of the New York Academy of Sciences
Volume963
Publication statusPublished - 2002

Keywords

  • Breast cancer
  • Objective response
  • Surrogate endpoints

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'Objective response to treatment as a potential surrogate marker of survival in breast cancer'. Together they form a unique fingerprint.

Cite this